Weight Loss Drugs Show Promise for Treating Addiction Across Multiple Substances

Medications widely prescribed for weight loss and diabetes management may offer a breakthrough approach to treating substance use disorders across all major addictive substances, according to a large-scale study published this week in The BMJ.

The research, which analyzed data from more than 600,000 veterans followed for up to three years, found that patients who started taking GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were 15% to 20% less likely to develop substance use disorders involving alcohol, nicotine, cannabis, cocaine, or opioids compared to those taking a different class of diabetes medication.

Among people with a history of substance use disorder, GLP-1 users experienced 25% to 50% lower rates of emergency department visits, hospitalizations, drug overdoses, suicidal thoughts or attempts, and death.

"The surprise was that it was working across various substances," said Dr. Ziyad Al-Aly, the study's lead author and a clinical epidemiologist at Washington University School of Medicine in St. Louis, who also holds a position at VA St. Louis Health Care System. "That really elevates the notion that these medications are acting on the root causes of all of these addictions."

A Common Biological Pathway

The study's most striking implication is that a single medication could address multiple substance use disorders simultaneously—a capability no existing treatment currently offers. Current addiction medications target specific substances: naltrexone for alcohol and opioids, buprenorphine for opioids, nicotine patches for smoking. The Food and Drug Administration has approved no medications at all for treating cannabis, stimulant, or sedative use disorders.

"Even with the drugs we have for alcohol use disorder and opioid use disorder, relapse rates are really high," said Alex DiFeliceantonio, an assistant professor at Virginia Tech's Fralin Biomedical Research Institute who was not involved in the study.

The research arrives as 48.4 million Americans live with a substance use disorder, yet fewer than 10% receive any form of treatment, according to the National Institute on Drug Abuse. The treatment gap reflects a combination of stigma, cost barriers, provider shortages, and the limited effectiveness of existing interventions.

Researchers used a novel methodology called emulated target trials, which applies randomized clinical trial methods to analyze existing medical records. The team simulated seven clinical trials comparing GLP-1 drugs to sodium-glucose cotransporter-2 inhibitors (SGLT2s), another class of diabetes medication, in veterans with Type 2 diabetes. The average patient age was 65, and 90% were male.

From Food Noise to Substance Cravings

The mechanism appears to involve the brain's reward signaling system. GLP-1 drugs work by mimicking a hormone that regulates blood sugar and appetite, but they also appear to modulate dopamine activity in neural circuits responsible for reward, motivation, and stress response.

"In obesity, when people take GLP-1 agonists, they describe the quieting of food noise, that constant chatter in their brain saying, 'I'm thinking about what to eat,'" Al-Aly explained. "I think something similar is happening with that preoccupation with needing a substance. It quiets."

This "hijacked" reward system is central to addiction biology, he noted. By dampening dopamine signaling in these pathways, GLP-1 medications may reduce the intensity of cravings across all substances that activate the same neural circuitry.

The hypothesis aligns with years of anecdotal reports from patients taking GLP-1 drugs for weight loss or diabetes control. Physicians began noticing patterns: patients spontaneously reporting they no longer felt the urge to drink alcohol, had quit smoking, or lost interest in recreational drugs.

"They would say, 'I don't care for alcohol anymore' or 'I stopped smoking,'" Al-Aly recalled. Those consistent observations prompted the current investigation.

Beyond Prevention: Treating Existing Disorders

While the study found GLP-1 drugs reduced the risk of developing new substance use disorders, the more robust finding involved people already struggling with addiction. This population saw dramatic reductions in acute medical crises and death.

"There's every reason to be incredibly enthusiastic," said Dr. Klara Klein, an endocrinologist at the UNC School of Medicine in Chapel Hill. But she cautioned that GLP-1 drugs have not yet been tested specifically in people without overweight, obesity, or Type 2 diabetes—the populations for whom they are currently FDA-approved.

Weight loss presents a particular concern for people with alcohol use disorder. "If they really stop drinking, they lose a lot of the calories that they intake from alcohol," Klein noted. "That person might lose really a lot of weight and suffer nutritionally."

The duration of treatment also remains uncertain. "My hope is that we'll figure out ways that a young person won't have to be on a medication for the rest of their lives," Klein said.

Clinical Trials Underway

The current study's observational design—despite its large scale—cannot definitively prove that GLP-1 drugs cause reductions in substance use. Controlled clinical trials are the gold standard for establishing efficacy and safety.

"I think of it as the strongest form of observational evidence, but still something we want to confirm with randomized trials," said Fares Qeadan, an associate professor of biostatistics at Loyola University Chicago's Parkinson School of Health Sciences and Public Health, who wrote an editorial accompanying the study.

Multiple clinical trials are already underway. Christian Hendershot, director of clinical research at the USC Institute for Addiction Science in Los Angeles, said results from these rigorous studies will roll out over the next few years.

"An accumulating body of studies are showing positive potential for using GLP-1s for substance use," Hendershot said. But he emphasized that addiction is complex, with different biological and social drivers for different people. "It's difficult to develop any one medication, especially for substance use disorder, that works for everyone."

Dr. Lorenzo Leggio, an addiction researcher at the National Institutes of Health who was not involved in the study, expressed cautious optimism. "We have a lot of hope that these medications may be helpful," he said. If confirmed, GLP-1 drugs could reshape treatment for people who use multiple substances—a common pattern that existing single-substance therapies struggle to address.

Implications for Addiction Medicine

If clinical trials validate the VA study findings, GLP-1 drugs could fill critical gaps in the addiction treatment landscape. They would be the first medications approved for cannabis and stimulant use disorders, conditions currently treated only through behavioral interventions.

They might also offer a relapse prevention tool superior to existing options. The study suggested GLP-1 drugs could reduce the chances of a substance use disorder resurfacing in people with prior histories, even if they initially took the medication for diabetes or weight management rather than addiction.

However, access remains a barrier. GLP-1 drugs are expensive—often exceeding $1,000 per month without insurance—and supply shortages have limited availability even for FDA-approved indications. Expanding use to addiction treatment would require insurers and government health programs to cover the medications for this purpose, a process that typically follows FDA approval for the specific indication.

The VA population studied—predominantly older men with diabetes—also limits generalizability to younger people, women, and those without metabolic conditions. Ongoing trials will need to demonstrate safety and efficacy across diverse demographics before GLP-1 drugs become a standard addiction treatment.

For now, the research represents a significant step toward understanding addiction as a brain disease with common biological underpinnings, rather than a collection of substance-specific disorders. The possibility that a single medication could address that shared biology offers hope to millions struggling with multiple addictions simultaneously.

As Leggio noted, "It's rare to see a patient only be addicted to one drug as opposed to using multiple drugs at the same time." With GLP-1 drugs, it may eventually be possible to help these people with a single medication—a transformation that would parallel the drugs' revolutionary impact on diabetes and weight loss.